Artivion

Artivion, Inc. focuses on developing solutions that address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment provides cardiac and vascular tissue preservation services. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Artivion reports strong revenue growth, FDA engagement on trial data

Artivion's Q4 2022 performance reflects solid revenue growth and improved margins, despite trial setbacks.
The company's strategic focus on innovation and expansion presents long-term growth opportunities.
Challenges with trial outcomes and FDA discussions highlight regulatory complexities impacting approvals.
Engagement with the FDA to address trial data issues could pave the way for future product launches.

Artivion (AORT) reports strong Q1 performance and eyes FDA approvals for growth

Artivion's Q1 performance showcases steady growth and strategic focus on product approvals and market expansion. Despite challenges in margins and debt, the company's outlook remains optimistic, with raised guidance for revenue and EBITDA. Key opportunities lie in FDA approvals and targeted growth in emerging markets.

Artivion excels in Q2 2023, raises revenue guidance for growth

Artivion's Q2 2023 performance reflects robust revenue growth, improved profitability, and enhanced cash position, setting the stage for future success.
The company's focus on innovation, clinical trials progress, and raised revenue guidance underscore its commitment to sustained growth and market leadership.
With strong financial fundamentals and a positive outlook for revenue and EBITDA, Artivion is well-positioned to capitalize on market opportunities and drive shareholder value.
Artivion's strategic initiatives and product advancements position it for continued success, supported by a solid financial foundation and a focus on operational efficiency.

Artivion reports robust Q3 results, eyes double-digit growth in 2024

Artivion's Q3 2023 performance was strong, with revenue growth and positive clinical data driving optimism for future growth and market share gains.
While challenges exist in balancing profitability and growth, the company's focus on top-line revenue growth and market expansion presents opportunities for sustained success.
With a clear roadmap for continued momentum in 2024, Artivion aims for double-digit revenue growth and $75 million EBITDA, supported by product innovation and market strategies.

Artivion reports robust 2023 growth, eyes market expansion and innovation

Artivion's strong financial performance in 2023, coupled with positive clinical trial results, sets a solid foundation for future growth.
The company's focus on innovation, market expansion, and optimized portfolio positions it well for continued success in 2024 and beyond.
Challenges with hemiarch procedures and the DANE connection underscore the importance of ongoing research and development efforts.
With a strategic approach to market growth and product development, Artivion is poised to capitalize on emerging opportunities and drive value for stakeholders.

Artivion reports robust Q1 performance, eyes growth in key markets

Artivion's Q1 2024 performance reflects strong revenue and EBITDA growth, driven by key product segments and regions. Positive clinical trial results and raised revenue guidance indicate a promising outlook. Challenges include regional revenue fluctuations and cash flow concerns.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

ATLANTA, Feb. 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2021 financial results will be released on Thursday, February 17, 2022 after the market closes.  On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2021 Financial Results

News for Artivion Stock (AORT)